Breast cancer treatment-induced cardiotoxicity.

Auteurs : Martel S, Maurer C, Lambertini M, Pondé N, de Azambuja E
Jaar : 2017
Journal : Expert Opin Drug Saf
Volume : 16(9)
Pagina's : 1021-1038

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Auteurs : Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber Rd, Piccart-Gebhart M, Baselga J
Jaar : 2017
Journal : N Engl J Med
Volume : 377(2)
Pagina's : 122-131

Adjuvant trastuzumab: a 10-year overview of its benefit.

Auteurs : Lambertini M, Pondé NF, Solinas C, de Azambuja E
Jaar : 2017
Journal : Expert Rev Anticancer Ther
Volume : 17
Pagina's : 61-74

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C
Jaar : 2017
Journal : JAMA Oncol
Volume : 3
Pagina's : 227-234

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Auteurs : Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M
Jaar : 2016
Journal : ESMO Open
Volume : 1
Pagina's : e000107

Phosphoethanolamine and the danger of unproven drugs.

Auteurs : Pondé N, de Azambuja E, Ades F
Jaar : 2016
Journal : Ecancermedicalscience
Volume : 10
Pagina's : 681

I-SPY 2: optimising cancer drug development in the 21st century.

Auteurs : Bartsch R, de Azambuja E
Jaar : 2016
Journal : ESMO Open
Volume : 1
Pagina's : e000113

Threat posed by unproven drugs in medical oncology.

Auteurs : Pondé N, Ades F, de Azambuja E
Jaar : 2016
Journal : ESMO Open
Volume : 1
Pagina's : e000064

Twenty years of anti-HER2 therapy-associated cardiotoxicity.

Auteurs : Pondé NF, Lambertini M, de Azambuja E
Jaar : 2016
Journal : ESMO Open
Volume : 1
Pagina's : e000073

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.

Auteurs : Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, Poggio F, Bonotto M, Floris G, Van Asten K, Wildiers H, Neven P, de Azambuja E, Paesmans M, Azim HA Jr
Jaar : 2016
Journal : Br J Cancer
Volume : 115(12)
Pagina's : 1471-78

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Auteurs : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Jaar : 2016
Journal : PLoS One
Volume : 11(7)
Pagina's : e0154009

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Auteurs : Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart-Gebhart M, Azim HA Jr
Jaar : 2016
Journal : J Natl Cancer Inst
Volume : 108

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Auteurs : Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart-Gebhart M, Dowsett M, Michiels S, Leyland-Jones B
Jaar : 2016
Journal : JAMA Oncol
Volume : 2(8)
Pagina's : 1040-7

The current use and attitudes towards tumor genome sequencing in breast cancer.

Auteurs : Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart-Gebhart M, Sotiriou C, Ignatiadis M, Azim HA Jr
Jaar : 2016
Journal : Sci Rep
Volume : 6
Pagina's : 22517

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Auteurs : Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart-Gebhart M, Gelber Rd
Jaar : 2016
Journal : Breast Cancer Res Treat
Volume : 155
Pagina's : 127-32

Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries.

Auteurs : Antoine C, Ameye L, Paesmans M, de Azambuja E, Rozenberg S
Jaar : 2016
Journal : Maturitas
Volume : 84
Pagina's : 81-8

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Auteurs : Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, Mcfadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber Rd, Perez EA
Jaar : 2016
Journal : J Clin Oncol
Volume : 34(10)
Pagina's : 1034-42

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.

Auteurs : Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ
Jaar : 2016
Journal : Oncotarget
Volume : 7(11)
Pagina's : 13209-20

An update on PARP inhibitors-moving to the adjuvant setting.

Auteurs : Sonnenblick A, de Azambuja E, Azim HA, Piccart-Gebhart M
Jaar : 2015
Journal : Nat Rev Clin Oncol
Volume : 12(1)
Pagina's : 27-41

Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.

Auteurs : de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M
Jaar : 2015
Journal : Eur J Cancer
Volume : 51
Pagina's : 2517-24